China Pharma Holding (STU:XQJ) Moat Score: 2/10 (As of Jul. 11, 2026)


STU:XQJ China Pharma Holding Inc STU:XQJ
26 GF Score
Price €26.80
GF Value €10.05
! 3 Warning Signs
View Full Analysis

What is China Pharma Holding Moat Score?

China Pharma Holding STU:XQJ 26 Moat Score is 2 as of Jul. 11, 2026. GuruFocus rates STU:XQJ with a GF Score™ of 26/100 and a GF Value™ of €10.05. The stock has 3 warning signs investors should review. Among 1,031 Drug Manufacturers companies, China Pharma Holding ranks better than 81.57% on this metric.

China Pharma Holding has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

China Pharma Holding has No Moat: China Pharma Holding Inc has very weak competitive advantages with no significant market leadership, customer loyalty, or regulatory barriers, resulting in a transient advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes China Pharma Holding might have No Moat - Very weak/transient advantages.

China Pharma Holding  (STU:XQJ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

China Pharma Holding Moat Score Related Terms

STU:XQJ vs TXMD, RMTI, AYTU: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Pharma Holding Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Moat Score distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Moat Score falls into.


STU:XQJ
26GF Score
China Pharma Holding Inc STU:XQJ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
China Pharma Holding (STU:XQJ) has a Moat Score of 2 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, China Pharma Holding ranks #190 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.4%.
Is China Pharma Holding's Moat Score too high?
China Pharma Holding's current Moat Score is 2. Based on the distribution chart, China Pharma Holding ranks #190 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Pharma Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Moat Score compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #190 out of 1031 companies for Moat Score. This places China Pharma Holding in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. China Pharma Holding's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current Moat Score of 2. The stock's GF Value™ is €10.05, compared to a current price of €26.80 — trading 166.7% above its estimated fair value. The current Moat Score is 2. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current Moat Score is 2 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Pharma Holding (STU:XQJ) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of €26.80 is trading 166.7% above its estimated GF Value™ of €10.05.

Key valuation signals for STU:XQJ:

  • Moat Score: 2
  • GF Value™: €10.05 vs. price of €26.80 (166.7% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Other Exchanges CPHI:USA
Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for STU:XQJ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.80
Price
€10.05
GF Value